The benefits of aspirin in protecting against thrombotic occlusions are well-established. However, aspirin use has also been linked to increased gastrointestinal and fatal bleeding in elderly patients. Safer preventive approaches should be considered in the elderly population, including reductions in aspirin dose, alternative daily regimens, and individualized treatment strategies.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hennekens, C. H. et al. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation 80, 749–756 (1989).
Sarbacker, G. B., Lusk, K. A., Flieller, L. A. & Van Liew, J. R. Aspirin use for the primary prevention of cardiovascular disease in the elderly. Consult. Pharm. 31, 24–32 (2016).
Li, L. et al. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet http://dx.doi.org/10.1016/S0140-6736(17)30770-5 (2017).
Serebruany, V. L. et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am. J. Cardiol. 95, 1218–1222 (2005).
Marciniak, T. A. et al. Drug discontinuation and follow-up rates in oral antithrombotic trials. JAMA Intern. Med. 176, 257–259 (2016).
US Food and Drug Administration. NDA 294–886. Cross-discipline Team Leader review on Vorapaxar. FDA http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204886Orig1s000SumR.pdf (2014).
Kirchheiner, J. et al. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur. J. Clin. Pharmacol. 65, 19–31 (2009).
Gomm, W. et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 73, 410–416 (2016).
Serebruany, V. L. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? Am. J. Med. 119, 113–116 (2006).
Serebruany, V. L. et al. Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial. Am. Heart J. 151, 92–99 (2006).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
V.S. is listed as an inventor for the issued US patent 'Treating vascular events with statins by inhibiting PAR-1 and PAR-4′ (7,842,716) and 'Method for treatment of platelet activity with E5555' (USN 61/080,791); assigned to Eisai. He received compensation for the issued U.S. patent 11/996,380 'Use of PAR-1/PAR-4 inhibitors for treating and preventing vascular diseases' on prasugrel assigned to Lilly. He received consultant and lecture fees from Aralez, AstraZeneca, Bayer, Daichii Sankyo, Lilly, Merck, and Sanofi. E.G. declares no competing interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Serebruany, V., Golukhova, E. Aspirin in the elderly — tailored approaches ahead?. Nat Rev Cardiol 14, 571–572 (2017). https://doi.org/10.1038/nrcardio.2017.117
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2017.117